Literature DB >> 26520372

Influence of radiation quality on mouse chromosome 2 deletions in radiation-induced acute myeloid leukaemia.

Natalie Brown1, Rosemary Finnon1, Grainne Manning1, Simon Bouffler1, Christophe Badie2.   

Abstract

Leukaemia is the prevailing neoplastic disorder of the hematopoietic system. Epidemiological analyses of the survivors of the Japanese atomic bombings show that exposure to ionising radiation (IR) can cause leukaemia. Although a clear association between radiation exposure and leukaemia development is acknowledged, the underlying mechanisms remain incompletely understood. A hemizygous deletion on mouse chromosome 2 (del2) is a common feature in several mouse strains susceptible to radiation-induced acute myeloid leukaemia (rAML). The deletion is an early event detectable 24h after exposure in bone marrow cells. Ultimately, 15-25% of exposed animals develop AML with 80-90% of cases carrying del2. Molecular mapping of leukaemic cell genomes identified a minimal deleted region (MDR) on chromosome 2 (chr2) in which a tumour suppressor gene, Sfpi1 is located, encoding the transcription factor PU.1, essential in haematopoiesis. The remaining copy of Sfpi1 has a point mutation in the coding sequence for the DNA-binding domain of the protein in 70% of rAML, which alters a single CpG sequence in the codon for arginine residue R235. In order to identify chr2 deletions and Sfpi.1/PU.1 loss, we performed array comparative genomic hybridization (aCGH) on a unique panel of 79rAMLs. Using a custom made CGH array specifically designed for mouse chr2, we analysed at unprecedentedly high resolution (1.4M array- 148bp resolution) the size of the MDR in low LET and high-LET induced rAMLs (32 X-ray- and 47 neutron-induced). Sequencing of Sfpi1/PU.1DNA binding domain identified the presence of R235 point mutations, showing no influence of radiation quality on R235 type or frequency. We identified for the first time rAML cases with complex del2 in a subset of neutron-induced AMLs. This study allowed us to re-define the MDR to a much smaller 5.5Mb region (still including Sfpi1/PU.1), identical regardless of radiation quality. Crown
Copyright © 2015. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Chromosome deletion; Mouse model; Myeloid leukemia; Radiation; Sfpi1/PU.1; aCGH

Mesh:

Substances:

Year:  2015        PMID: 26520372     DOI: 10.1016/j.mrgentox.2015.07.012

Source DB:  PubMed          Journal:  Mutat Res Genet Toxicol Environ Mutagen        ISSN: 1383-5718            Impact factor:   2.873


  4 in total

1.  Is Toxoplasma Gondii Infection a Risk Factor for Leukemia? An Evidence-Based Meta-Analysis.

Authors:  Yi Huang; Yu Huang; Aoshuang Chang; Jishi Wang; Xiaoqing Zeng; Jiahong Wu
Journal:  Med Sci Monit       Date:  2016-05-07

2.  Knockdown of SNHG16 suppresses the proliferation and induces the apoptosis of leukemia cells via miR‑193a‑5p/CDK8.

Authors:  Meihua Piao; Li Zhang
Journal:  Int J Mol Med       Date:  2020-07-08       Impact factor: 4.101

3.  Kras mutations and PU.1 promoter methylation are new pathways in murine radiation-induced AML.

Authors:  Gráinne O'Brien; Lourdes Cruz-Garcia; Joanna Zyla; Natalie Brown; Rosemary Finnon; Joanna Polanska; Christophe Badie
Journal:  Carcinogenesis       Date:  2020-08-12       Impact factor: 4.944

4.  Tracking preleukemic cells in vivo to reveal the sequence of molecular events in radiation leukemogenesis.

Authors:  Tom Verbiest; Rosemary Finnon; Natalie Brown; Lourdes Cruz-Garcia; Paul Finnon; Grainne O'Brien; Eleanor Ross; Simon Bouffler; Cheryl L Scudamore; Christophe Badie
Journal:  Leukemia       Date:  2018-03-03       Impact factor: 11.528

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.